Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

Author： Del Vecchio Lucia   Locatelli Francesco  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.11, Iss.6, 2012-11, pp. : 923-931

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations

By Abraham Ivo   MacDonald Karen  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 885-887

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-stimulating agents in patients with cancer: update on safety issues

By Pirker Robert  

Expert Opinion on Drug Safety, Vol. 8, Iss. 5, 2009-09 ,pp. : 515-522

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis

By Escudero-Vilaplana Vicente  

International Journal of Clinical Pharmacy, Vol. 35, Iss. 3, 2013-06 ,pp. : 463-468

Springer Publishing Company

Access to resources Recommend Favorite

Differentiating Factors Between Erythropoiesis-Stimulating Agents: A Guide to Selection for Anaemia of Chronic Kidney Disease

By Deicher R.   Hörl W.H.  

Drugs, Vol. 64, Iss. 5, 2004-01 ,pp. : 499-509

Adis International

Access to resources Recommend Favorite

Erythropoiesis-Stimulating Agents in Oncology

By Glaspy John A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 6, 2008-07 ,pp. : 565-575

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite